LEASE Between TRAFALGAR HOUSE REAL ESTATE, a division of TRAFALGAR HOUSE PROPERTY, INC. Landlord, andLease Agreement • May 15th, 1998 • Nexmed Inc • Pharmaceutical preparations • New Jersey
RECITALSPurchase Agreement • August 14th, 2002 • Nexmed Inc • Pharmaceutical preparations • New York
A WARRANTWarrant Agreement • December 23rd, 2004 • Nexmed Inc • Pharmaceutical preparations • New York
COMMON STOCK PURCHASE WARRANT SEELOS THERAPEUTICS, INC.Common Stock Purchase Warrant • July 12th, 2024 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockholder Approval Date (as defined below) (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the date that is [the five (5) year anniversary]/[eighteen (18) month anniversary] of the Stockholder Approval Date, provided that, if such date is not a Trading Day, the date that is the immediately following Trading Day (the “Termination Date”), but not thereafter, to subscribe for and purchase from Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock (as defined herein). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Pric
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 25th, 2023 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of September 21, 2023, between Seelos Therapeutics, Inc. a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
WARRANT to Purchase Common Stock of NEXMED, INC. Expiring July 27, 2003Warrant Agreement • July 19th, 2002 • Nexmed Inc • Pharmaceutical preparations • New York
FORM OF REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 21st, 2018 • Apricus Biosciences, Inc. • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of September ___, 2018, between Apricus Biosciences, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
RECITALSPurchase Agreement • January 13th, 2004 • Nexmed Inc • Pharmaceutical preparations • New York
RECITALSStock Purchase Agreement • March 16th, 2000 • Nexmed Inc • Pharmaceutical preparations • Hong Kong
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 21st, 2018 • Apricus Biosciences, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of September 20, 2018, between Apricus Biosciences, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
SEELOS THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of , 20 Debt SecuritiesIndenture • December 15th, 2020 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
INDENTURE, dated as of , 20 , by and between SEELOS THERAPEUTICS, INC., a Nevada corporation (the "Company"), and [TRUSTEE], as trustee (the "Trustee"):
EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT dated September 26, 2003 by and between NexMed, Inc., a Nevada corporation (the "Company") and Vivian H. Liu (the "Executive"). WHEREAS, the Company desires to continue to employ Executive and to enter into an...Employment Agreement • November 12th, 2003 • Nexmed Inc • Pharmaceutical preparations • New Jersey
B WARRANTWarrant Agreement • December 23rd, 2004 • Nexmed Inc • Pharmaceutical preparations • New York
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (the "Agreement") is made and entered into as of this 12th day of December, 2003 by and between NexMed, Inc., a Nevada corporation (the "Company"), and the "Purchasers"...Registration Rights Agreement • January 13th, 2004 • Nexmed Inc • Pharmaceutical preparations • New York
PRE-FUNDED COMMON STOCK PURCHASE WARRANT seelos therapeutics, inc.Pre-Funded Common Stock Purchase Warrant • May 21st, 2024 • Seelos Therapeutics, Inc. • Pharmaceutical preparations
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
INVESTOR RIGHTS AGREEMENT This Investor Rights Agreement (this "Agreement") is made and entered into as of December 17, 2004 among NexMed, Inc., a Nevada corporation (the "Company"), and each of the purchasers executing this Agreement and listed on...Investor Rights Agreement • December 23rd, 2004 • Nexmed Inc • Pharmaceutical preparations • New York
COMMON STOCK PURCHASE WARRANT seelos therapeutics, inc.Common Stock Purchase Warrant • May 21st, 2024 • Seelos Therapeutics, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on May 21, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Warrant No. W-_ COMMON STOCK PURCHASE WARRANT To Purchase _________ Shares of Common Stock of NEXMED, INC. THIS IS TO CERTIFY THAT __________________, or registered assigns (the "Holder"), is entitled, during the Exercise Period (as hereinafter...Warrant Agreement • May 14th, 2003 • Nexmed Inc • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • May 12th, 2022 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT SEELOS THERAPEUTICS, INC.Securities Agreement • July 12th, 2024 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockholder Approval Date (as defined below) (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the date that is the five (5) year anniversary of the Stockholder Approval Date, provided that, if such date is not a Trading Day, the date that is the immediately following Trading Day (the “Termination Date”), but not thereafter, to subscribe for and purchase from Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock (as defined herein). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Sec
UNDERWRITING AGREEMENT between SEELOS THERAPEUTICS, INC. and TITAN PARTNERS GROUP LLC, A DIVISION OF AMERICAN CAPITAL PARTNERS, LLC as Representative of the Several Underwriters SEELOS THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • November 30th, 2023 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
The undersigned, Seelos Therapeutics, Inc., a corporation formed under the laws of the State of Nevada (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of Seelos Therapeutics, Inc. the “Company”), hereby confirms its agreement (this “Agreement”) with Titan Partners Group, LLC, a division of American Capital Partners, LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”), and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
15,243,903 Shares SEELOS THERAPEUTICS, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 26th, 2021 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
7,500,000 SHARES OF COMMON STOCK OF SEELOS THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • March 12th, 2020 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
The Benchmark Company, LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o The Benchmark Company, LLC 150 East 58th Street, 17th Floor New York, New York 10155
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • May 21st, 2024 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
ContractWarrant Agreement • October 20th, 2014 • Apricus Biosciences, Inc. • Pharmaceutical preparations • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 21st, 2024 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of May 16, 2024, between Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
COMMON STOCK AND WARRANT PURCHASE AGREEMENTCommon Stock and Warrant Purchase Agreement • June 25th, 2004 • Nexmed Inc • Pharmaceutical preparations • New York
COMMON STOCK PURCHASE WARRANT SEELOS THERAPEUTICS, INC.Common Stock Purchase Agreement • January 30th, 2024 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, __________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on January 30, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), up to __________ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • October 20th, 2014 • Apricus Biosciences, Inc. • Pharmaceutical preparations
THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of October 17, 2014 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including Oxford in its capacity as a Lender and SILICON VALLEY BANK, a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054 (“Bank” or “SVB”) (each a “Lender” and collectively, the “Lenders”), and APRICUS BIOSCIENCES, INC., a Nevada corporation, NEXMED (U.S.A.), INC., a Delaware corporation, NEXMED HOLDINGS, INC., a Delaware corporation and APRICUS PHARMACEUTICALS USA, INC., a Delaware corporation, each with offices located at 11975 El Camino Real, Suite 300, San Diego,
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • July 6th, 2016 • Apricus Biosciences, Inc. • Pharmaceutical preparations • Nevada
COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of July 5, 2016 by and between APRICUS BIOSCIENCES, INC., a Nevada corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (the “Buyer”). Capitalized terms used herein and not otherwise defined herein are defined in Section 10 hereof.
SHARES OF COMMON STOCK AND _____________ WARRANTS OF APRICUS BIOSCIENCES, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • April 20th, 2017 • Apricus Biosciences, Inc. • Pharmaceutical preparations • New York
The undersigned, Apricus Biosciences, Inc., a company incorporated under the laws of Nevada (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Apricus Biosciences, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which H.C. Wainwright & Co., LLC is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 6th, 2016 • Apricus Biosciences, Inc. • Pharmaceutical preparations • Nevada
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 5, 2016, by and between APRICUS BIOSCIENCES, INC., a Nevada corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Common Stock Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
SEELOS THERAPEUTICS, INC. EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • June 18th, 2019 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
As further set forth in this agreement (this "Agreement"), Seelos Therapeutics, Inc., a company organized under the laws of Nevada (the "Company"), proposes to issue and sell from time to time through Piper Jaffray & Co. (the "Agent"), as sales agent, shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), having an aggregate offering price of up to $50,000,000 (such shares of Common Stock to be sold pursuant to this Agreement, the "Shares") on terms set forth herein. Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in Section 2 of this Agreement on the number of Shares issued and sold under this Agreement shall be the sole responsibility of the Company, and the Agent shall have no obligation in connection with such compliance.
PURCHASE AGREEMENT NexMed, Inc. 350 Corporate Boulevard Robbinsville, New Jersey 08691 Ladies & Gentlemen: The undersigned purchaser (the "Purchaser") hereby confirms its agreement with you as follows: 1. This Purchase Agreement (the "Purchase...Purchase Agreement • August 14th, 2002 • Nexmed Inc • Pharmaceutical preparations • New York
INDEMNITY AGREEMENTIndemnity Agreement • August 31st, 2018 • Apricus Biosciences, Inc. • Pharmaceutical preparations • Delaware
This Indemnity Agreement (this “Agreement”) dated as of July 8, 2016, is made by and between Seelos Therapeutics, Inc., a Delaware corporation (the “Company”), and Raj Mehra (“Indemnitee”).
